Quick Answer
Adaptimmune Therapeutics PLC reported Cash and Equivalents of $91.14 million for fiscal year 2024.
Adaptimmune Therapeutics PLC Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2024 | $91.14M | -36.7% |
| 2023 | $143.99M | +33.3% |
| 2022 | $108.03M | -28.0% |
| 2021 | $149.95M | +163.6% |
| 2020 | $56.88M | +12.8% |
| 2019 | $50.41M | -26.3% |
| 2018 | $68.38M | -18.6% |
| 2017 | $84.04M | -47.1% |
| 2016 | $158.78M | -18.3% |
| 2015 | $194.26M | -15.2% |
| 2015 | $229.05M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| June 30, 2025 | $26.06M | -87.7% | -36.5% |
| March 31, 2025 | $41.05M | -70.8% | -55.0% |
| December 31, 2024 | $91.14M | -36.7% | -21.9% |
| September 30, 2024 | $116.74M | +29.6% | -44.9% |
| June 30, 2024 | $211.81M | +175.2% | +50.6% |
| March 31, 2024 | $140.67M | +17.4% | -2.3% |
| December 31, 2023 | $143.99M | +33.3% | +59.9% |
| September 30, 2023 | $90.06M | +14.0% | +17.0% |
- Adaptimmune Therapeutics PLC showed a decrease of -36.7% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2015–2024 period, Adaptimmune Therapeutics PLC’s cash and equivalents has declined by 60.2% (from $229.05 million to $91.14 million).
- The most recent figure is from Adaptimmune Therapeutics PLC’s fiscal year 2024 report (Form 10-K), filed with the SEC on March 24, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: